ADME Toxicology Testing Market Report 2026

The adme toxicology testing market size has grown rapidly in recent years. It will grow from $11.5 billion in 2025 to $12.83 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to limited availability of automated adme testing systems, reliance on traditional biochemical assays, increasing regulatory focus on drug safety, growing pharmaceutical research initiatives, adoption of lc-ms and hplc instruments.

The adme toxicology testing market size is expected to see rapid growth in the next few years. It will grow to $20.25 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to development of integrated adme platforms, rising application of omics and molecular imaging technologies, increasing investment in predictive toxicology software, expansion of adme testing in cosmetics and food industries, adoption of ai-driven risk assessment solutions. Major trends in the forecast period include growing adoption of high-throughput screening instruments, increasing use of cell-based and in vitro assays, rising demand for omics-based toxicology technologies, expansion of adme testing in pharmaceutical development, integration of simulation and modeling software in risk assessment.

The increasing demand for novel drugs is expected to drive the growth of the ADME toxicology testing market going forward. Novel drugs are pharmaceutical compounds that have not previously been approved or commercialized for therapeutic use. ADME toxicology testing represents a critical stage in the drug development process, as it evaluates whether a new drug is safe and ensures it does not generate harmful toxic effects within the body. For instance, in January 2024, according to the New Drug Therapy Approvals 2023 report released by the Center for Drug Evaluation and Research (CDER), a US-based division of the U.S. Food and Drug Administration (FDA), CDER approved 55 novel drugs in 2023, of which 20, or 36%, were classified as first-in-class, compared with 37 novel drug approvals in 2022. Therefore, the growing demand for novel drugs is fueling the expansion of the ADME toxicology testing market.

The expansion of the pharmaceutical industry is also expected to propel the growth of the ADME toxicology testing market going forward. The pharmaceutical industry encompasses the discovery, development, and manufacturing of drugs and medicines by both public and private organizations. Within this industry, ADME toxicology testing is widely used to evaluate the absorption, distribution, metabolism, and excretion characteristics of drug candidates, along with their potential toxicity. These assessments are essential for predicting how a drug will behave in the human body, including its absorption efficiency, distribution to target tissues, metabolic pathways, and elimination processes. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade body representing Europe’s pharmaceutical sector, total pharmaceutical production in Europe reached €390.0 billion ($422,803 million) in 2023, up from €363.3 billion ($393,857 million) in 2022. Therefore, the continued growth of the pharmaceutical industry is contributing to the expansion of the ADME toxicology testing market.

Major companies operating in the ADME toxicology testing market are introducing advanced technological integrations, such as the Cyprotex e-Store, to enable convenient online ordering of ADME-Tox services. ADME-Tox services are designed to reduce development timelines and costs, minimize the risk of late-stage drug failure, and support the selection of the most suitable candidates for clinical development. For instance, in October 2023, Evotec SE, a Germany-based biotechnology company, launched the Cyprotex e-Store, an e-commerce platform that offers simplified online access to its full range of ADME-Tox services. The platform streamlines and accelerates the purchasing process by allowing registered users to review and order services at any time, seven days a week. It provides immediate access to pricing and detailed protocols, while enabling users to place orders, monitor progress, and reorder services efficiently, thereby reducing lead times and allowing faster delivery of data.

Major companies operating in the adme toxicology testing market are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Laboratory Corporation of America Holdings, Corning Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Lonza Group AG, Dassault Systèmes SE, Catalent Inc., Charles River Laboratories International Inc., Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Curia Global Inc, Promega Corporation, Takara Bio Inc, AB Sciex LLC, QPS Holdings LLC, Simulations Plus Inc., Cyprotex, XenoTech LLC, BioIVT LLC, Absorption Systems, Creative Bioarray, SOLVO Biotechnology Rt., Creative Biolabs Inc, Gentronix Limited, Admecell Inc., Molecular Discovery Ltd.

North America was the largest region in the ADME toxicology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adme toxicology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adme toxicology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the adme toxicology testing market by increasing the costs of imported instruments, reagents, and high-throughput systems. Segments like lc-ms, hplc, and cell-based assay platforms are most affected, with regions such as north america, europe, and asia-pacific research hubs facing higher import duties. The resulting cost pressures have led to slower procurement and longer project timelines. On the positive side, tariffs are driving local manufacturing, encouraging regional supply chain development, and fostering innovation in software and assay technologies.

The adme toxicology testing market research report is one of a series of new reports that provides adme toxicology testing market statistics, including adme toxicology testing industry global market size, regional shares, competitors with a adme toxicology testing market share, detailed adme toxicology testing market segments, market trends and opportunities, and any further data you may need to thrive in the adme toxicology testing industry. This adme toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

ADME toxicology testing comprises a series of studies performed to evaluate the potential toxicity of a substance or drug candidate based on its absorption, distribution, metabolism, and excretion (ADME) characteristics. These tests are an essential part of drug development and are used to ensure the safety of individuals exposed to various substances.

The main products used in ADME toxicology testing include instruments, software solutions, assay systems, reagents, and others. Instruments are devices or tools specifically designed for scientific, medical, or technical purposes and are used in ADME toxicity testing to measure and analyze results. The testing methods include cellular assays, biochemical assays, in silico approaches, and ex vivo studies, supported by technologies such as single-cell culture, high-throughput systems, molecular imaging, omics technologies, and others. These tests are applied to evaluate systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and additional toxicity types across industries including cosmetics and household products, pharmaceuticals, animal health, food, and others.

The ADME toxicology testing market consists of revenues earned by entities by providing services such as drug discovery research, measuring gene expression, and preclinical efficacy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The ADME toxicology testing market also includes sales of ADMET predictors, and UV spectrophotometers, which are used in providing ADME toxicology testing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.